M Fedgchin

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
2094 Background: Several cancer chemotherapeutic agents are metabolized by CYP3A4. Co-administration of compounds that inhibit CYP3A4 may lead to decreased metabolic clearance, increased exposure, and increased toxicity of these antineoplastic agents. Aprepitant (EMEND), a recently approved antiemetic agent, moderately inhibits human CYP3A4 in vivo and in(More)
  • 1